Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Price Performance

TRVN stock opened at $1.69 on Wednesday. The business’s fifty day moving average price is $2.27 and its two-hundred day moving average price is $4.99. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The stock has a market capitalization of $1.46 million, a price-to-earnings ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million during the quarter. Research analysts expect that Trevena will post -23.04 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.